Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (FR:NANO)
:NANO
NANO Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.62 - €8.89
Previous CloseN/A
Volume30.64K
Average Volume (3M)264.97K
Market Cap
€349.88M
Enterprise ValueN/A
Total Cash (Recent Filing)€49.74M
Total Debt (Recent Filing)€50.90M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,943,150
10 Day Avg. Volume342,271
30 Day Avg. Volume264,972
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.50Price Target Upside-24.66% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical ProgressPositive NSCLC data updates continue to strengthen the thesis on NBTXR3, reiterating a buy recommendation.
Financial PositionThe probability of receiving significant milestone payments within the next 12-18 months is high, which could extend the company's financial runway through non-dilutive funds.
PartnershipsNanobiotix's partner, Johnson & Johnson, initiated a Phase 2 study which could lead to a significant milestone payment if successful.
Bears Say
Commercial RisksThere are risks identified in clinical, commercial, financial, partnership, and intellectual property areas.
Financial ChallengesRevenues in FY 24 were negatively impacted by a one-off recognition of a net liability linked to NANORAY-312's sponsorship transfer to J&J.
RisksRisks associated with the stock include clinical, commercial, financial, partnership, and intellectual property challenges.
Nanobiotix News
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €2.62 and its highest was €8.89 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €349.88M.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Overvalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 47,943,150 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
Company Description
Nanobiotix SA
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Technical Analysis
Genfit
―
Innate Pharma SA
―
Abivax SA
―
DBV Technologies
―
OSE Immunotherapeutics SA
―
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---